2 days Down -25.59% in 4 Weeks, Here’s Why CytomX Therapeutics (CTMX) Looks Ripe for a TurnaroundZacks
CytomX Therapeutics (CTMX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
X